STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
292,451 Orion Corporation A shares converted into B shares
In accordance with Section 3 of the Articles of
The total number of shares in
CFO | SVP, Corporate Functions |
Contact person:
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D currently are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to
© OMX, source